TCGA-OR-A5J5-01
Adrenocortical Carcinoma · Adrenocortical Carcinoma · Adrenocortical Carcinoma, Usual Type
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Adrenocortical Carcinoma
- cancer_type_detailed
- Adrenocortical Carcinoma
- subtype
- Adrenocortical Carcinoma, Usual Type
- cancer_type
- Adrenocortical Carcinoma
- cancer_type_detailed
- Adrenocortical Carcinoma
- subtype
- Adrenocortical Carcinoma, Usual Type
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.301
- HEDGEHOG_SIGNALING+0.212
- WNT_BETA_CATENIN_SIGNALING+0.154
- G2M_CHECKPOINT+0.134
- SPERMATOGENESIS+0.042
- APICAL_JUNCTION+0.011
- E2F_TARGETS-0.036
- UV_RESPONSE_UP-0.049
- PANCREAS_BETA_CELLS-0.057
- ESTROGEN_RESPONSE_LATE-0.085
Top 10 suppressed
- ANDROGEN_RESPONSE-0.519
- PROTEIN_SECRETION-0.478
- MTORC1_SIGNALING-0.476
- BILE_ACID_METABOLISM-0.437
- FATTY_ACID_METABOLISM-0.437
- CHOLESTEROL_HOMEOSTASIS-0.428
- ADIPOGENESIS-0.424
- OXIDATIVE_PHOSPHORYLATION-0.407
- PEROXISOME-0.399
- INTERFERON_ALPHA_RESPONSE-0.396
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_Q13FQ8FV | Diffuse intrinsic pontine glioma | — | 0.940 |
| 2 | SRR4195662 | — | — | 0.925 |
| 3 | d333233b-e431-462b-ae35-c3b4c6ab3a40 | — | — | 0.917 |
| 4 | SRR4195643 | — | — | 0.906 |
| 5 | TCGA-90-A4ED-01A-31R-A24Z-07 | — | cohortMD1 | 0.906 |
| 6 | BS_9CA93S6D | Diffuse intrinsic pontine glioma | — | 0.896 |
| 7 | MDT-AP-2067 | Med | Medulloblastoma | 0.895 |
| 8 | SRR12696758 | — | — | 0.892 |
| 9 | BS_J71N7D09 | medulloblastoma | — | 0.891 |
| 10 | TCGA-21-5782-01A-01R-1635-07 | — | cohortSC | 0.891 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 6 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.301 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.212 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.154 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.134 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.042 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.011 | Inavolisib | — uncovered |